

Supplementary Information

A new class of 7-deazaguanine agents targeting autoimmune diseases: dramatic reduction of synovial fibroblast IL-6 production from human rheumatoid arthritis patients and improved performance against murine experimental autoimmune encephalomyelitis.

Michelle Cotter,^a Shauna M. Quinn,^b Ursula Fearon,^c Sharon Ansboro,^c Tatsiana Rakovic,^c John M. Southern,^{a} Vincent P. Kelly^{b*} and Stephen J. Connon^{*a}*

^aSchool of Chemistry, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College, Dublin, Ireland

^bSchool of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College, Dublin, Ireland

^cSchool Medicine, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College, Dublin, Ireland

Table of Contents

1.0	Figure S1: PBMC cell viability assays for selected compounds	2
2.0	Figure S2: Analysis of animal weights in the EAE study	2
3.0	¹ H and ¹³ C spectra of compounds 6 , 17 , 21 , 25 and 26	5









Figure S1: PBMC cell viability assays for selected compounds








Figure S2: Weights of animals, data represent the mean \pm s.e.m.

¹H and ¹³C NMR (DMSO-*d*₆) spectra for compounds 6, 17, 21, 25 and 26

